Whereas siRNA and shRNA molecules can be obtained quickly and reasonably affordably, the generation of small-molecule inhibitors for specific proteins requires a more substantial investment.

Dublin, April 18, 2025 (GLOBE NEWSWIRE) -- The "Small Molecule Innovator API CDMO Market Size, Share & Trends Analysis Report 2025-2030" has been added to ResearchAndMarkets.com's offering.

PRISM BioLab & Elix join forces to speed up AI-driven drug discovery for protein-protein interaction targets: Tokyo, Japan Tuesday, April 15, 2025, 16:00 Hrs [IST] PRISM BioLab, C ...

Attempts over the years to design "small molecule" drugs that block them ... Their previous work identified reversible inhibitors of cJun, but this latest work builds on that by discovering ...

Attempts over the years to design small molecule drugs that block them have ... Their previous work identified reversible inhibitors of cJun, but this latest work builds on that by discovering ...

The firm is also involved in the development of small molecule inhibitors of galectin-3 and LOXL2. The company was founded by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård ...

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial ...